Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lee, E. S.
Right arrow Articles by Lernmark, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, E. S.
Right arrow Articles by Lernmark, A.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 48, Issue 1 43-49, Copyright © 1999 by American Diabetes Association

ARTICLES

Recombinant human platelet-activating factor acetylhydrolase reduces the frequency of diabetes in the diabetes-prone BB rat

ES Lee, J Jiang, GC Sund, WT Simonson, J Graham, G Dietsch, B Schimpf, S Bieg, G Peterman and A Lernmark
Department of Medicine, University of Washington, Seattle 98195, USA.

Platelet-activating factor (PAF) has been implicated in the development of type 1 diabetes. Our previous studies have suggested that PAF inhibitors reduce insulitis and the frequency of diabetes in BB rats. In this study, serum PAF levels were reduced to address the hypothesis that PAF is important for the development of insulitis. From the age of 35 days on, DP-BB rats were treated with human recombinant PAF acetylhydrolase (rPAF-AH), which efficiently inactivates PAF. Our data indicate that intraperitoneal injections of rPAF-AH reduce the incidence of diabetes in the DP-BB rat. Daily intraperitoneal injections of 6.0 mg/kg body wt rPAF-AH reduced the frequency of diabetes in saline-injected rats from 90% (27/30) to 57% (17/30) (P = 0.004). As found by morphometric analysis on pancreatic islets, DP-BB rats protected from diabetes had less severe degrees of insulitis in a dose-dependent manner. DP-BB rats protected by rPAF-AH also had a higher percentage of insulin-positive cells in pancreas sections compared with those from diabetic animals. We therefore speculated that the beta-cells were protected from insulitis by rPAF-AH.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
J. M. Fuller, A. E. Kwitek, T. J. Hawkins, D. H. Moralejo, W. Lu, T. D. Tupling, A. J. MacMurray, G. Borchardt, M. Hasinoff, and A. Lernmark
Introgression of F344 Rat Genomic DNA on BB Rat Chromosome 4 Generates Diabetes-Resistant Lymphopenic BB Rats
Diabetes, December 1, 2006; 55(12): 3351 - 3357.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
B. Ersoy, A. Huseyinov, and S. Darcan
The Role of Platelet-Activating Factor in Pathogenesis of Type 1 Diabetes
Diabetes Care, April 1, 2005; 28(4): 980 - 980.
[Full Text] [PDF]

Home page
 DiabetesHome page
M. Grattan, Q.-S. Mi, C. Meagher, and T. L. Delovitch
Congenic Mapping of the Diabetogenic Locus Idd4 to a 5.2-cM Region of Chromosome 11 in NOD Mice: Identification of Two Potential Candidate Subloci
Diabetes, January 1, 2002; 51(1): 215 - 223.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1999 by the American Diabetes Association.